Patrick G. Enright, Director at Vera Therapeutics, Inc. (VERA), bought 500,000 shares at $20.87 ($10.6M) on 2025-06-23, disclosed to the SEC on 2025-06-25.
Open-market purchase of $10.6M VERA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.87 | 69,798 | $1.5M | 13.8% |
| 2 | $20.87 | 69,798 | $1.5M | 13.8% |
| 3 | $20.87 | 139,595 | $2.9M | 27.6% |
| 4 | $20.87 | 139,595 | $2.9M | 27.6% |
| 5 | $22.35 | 13,536 | $303K | 2.9% |
| 6 | $22.35 | 13,536 |
| $303K |
| 2.9% |
| 7 | $22.35 | 27,071 | $605K | 5.7% |
| 8 | $22.35 | 27,071 | $605K | 5.7% |
| Total | $21.11 avg | 500,000 | $10.6M | 100% |
| Filing → |
| ZBIO | BUY | 2025-10-14 | $2.5M | — | Filing → |
| BIOA | BUY | 2024-09-27 | $7.2M | — | Filing → |
| ZBIO | BUY | 2024-09-16 | $7.5M | — | Filing → |